Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C
- 2 May 2002
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 54 (4) , 571-586
- https://doi.org/10.1016/s0169-409x(02)00028-5
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter studyGastroenterology, 2001
- PegylationClinical Pharmacokinetics, 2001
- Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (pegasysTM) and thrice weekly interferon alfa-2a (roferonTM) in patients with chronic hepatitis C and compensated cirrhosisGastroenterology, 2000
- The effect of successful anti-viral therapy on health-related quality of life for patients with chronic hepatitis C and cirrhosisGastroenterology, 2000
- Design of the halt-C trial (Hepatitis C antiviral long-term treatment to prevent Cirrhosis)Gastroenterology, 2000
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- A pharmacokinetic model for alpha interferon administered subcutaneouslyBritish Journal of Clinical Pharmacology, 1999
- Influence of Human Serum Albumin Content in Formulations on the Bioequivalency of Interferon Alfa‐2a Given by Subcutaneous Injection in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1995
- Clinical Pharmacokinetics of InterferonsClinical Pharmacokinetics, 1990